<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03044834</url>
  </required_header>
  <id_info>
    <org_study_id>35RC15_3009_PPB</org_study_id>
    <secondary_id>15.18</secondary_id>
    <secondary_id>15.468</secondary_id>
    <secondary_id>915465</secondary_id>
    <nct_id>NCT03044834</nct_id>
  </id_info>
  <brief_title>Review of the Paediatric Pleuropulmonary Blastoma French Series</brief_title>
  <acronym>PPB</acronym>
  <official_title>Review of the Paediatric Pleuropulmonary Blastoma French Series</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pleuropulmonary blastoma is a rare embryonic malignant tumour that remains the most frequent&#xD;
      malignant tumour of the lung in childhood. The International Pleuro pulmonary Blastoma&#xD;
      Registry (IPPB) found only 220 cases in 2009 and 350 in 2015. In France, 20 cases were&#xD;
      identified in 2009.&#xD;
&#xD;
      Three histologies are described: type 1 purely cystic, type 2 combined and type 3 solid.&#xD;
      Median age at diagnostic is 12 months, 35 months and 41 months respectively. Evolution is&#xD;
      possible from type 1 to type 2 or 3 in 10% of the cases.&#xD;
&#xD;
      Since 2009, DICER 1 mutations research is proposed systematically to all families.&#xD;
&#xD;
      PPB symptoms are usually non-specific. Diagnostic is evoked when imaging work up shows&#xD;
      bubbles or solid lesions, and confirmed by pathological analysis. However the diagnosis can&#xD;
      be difficult because of the proximity with congenital cystic adenomatoid malformation.&#xD;
&#xD;
      The French society of paediatric oncology recommends surgery at first instance. PPB type 1&#xD;
      remains a problem because some are still misdiagnosed as CCAM, a benign lesion. Chemotherapy&#xD;
      depends on the PPB type and the quality of the resection. There is a real interest to analyse&#xD;
      the French series.&#xD;
&#xD;
      The prognosis of type 2 and 3 is low with a 5 years survival rate of 45-60%, whereas type 1&#xD;
      survival rate is 91%. The French experience reports a 100% survival rate in type 1 and 48% in&#xD;
      type 2 and 3. Other prognostic factors are initial size of the tumour, extra pulmonary&#xD;
      invasion and quality of surgery.&#xD;
&#xD;
      Early local relapses are possible and late ones concern more often type 2 and 3 with more&#xD;
      cerebral metastasis.&#xD;
&#xD;
      In 2009, the french cases were collected, but no update has been performed since. The aim of&#xD;
      this retrospective review of the cases since 2000, is to audit the care of PPB patients in&#xD;
      France and update the French rare tumour database.&#xD;
&#xD;
      Evoking PPB diagnosis is difficult when imaging shows a neonatal cystic lesion. There are no&#xD;
      radiologic criteria in the literature that differentiate congenital pulmonary cystic lesion&#xD;
      and PPB type 1. Radiological presentation is however overlapping. Another aim of this study&#xD;
      will be to look for a predictive sign of type 1 PPB.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentre retrospective study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">July 9, 2018</completion_date>
  <primary_completion_date type="Actual">February 22, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Within 5 years from the diagnosis</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Within 5 years from the diagnosis</time_frame>
    <description>Characterize the evolution and the global care of PPB in the French series</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>State of PPB surgical care</measure>
    <time_frame>Within 5 years from the diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiology sign</measure>
    <time_frame>Within 5 years from the diagnosis</time_frame>
    <description>Identification of a type 1 PPB predictive radiological sign</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">41</enrollment>
  <condition>Pleuropulmonary Blastoma</condition>
  <arm_group>
    <arm_group_label>Pleuropulmonary Blastoma</arm_group_label>
    <description>Patients born between 01/01/2000 and 01/01/2016 ;&#xD;
Followed up for PPB&#xD;
Treated in a French department of paediatric oncology or paediatric surgery&#xD;
Study agreement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PPB</intervention_name>
    <description>Global current care</description>
    <arm_group_label>Pleuropulmonary Blastoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients born between 01/01/2000 and 01/01/2016, followed up for PPB, treated in a French&#xD;
        department of paediatric oncology or paediatric surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients born between 01/01/2000 and 01/01/2016 ;&#xD;
&#xD;
          -  Followed up for PPB&#xD;
&#xD;
          -  Treated in a French department of paediatric oncology or paediatric surgery&#xD;
&#xD;
          -  Study agreement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Part of the care out of France&#xD;
&#xD;
          -  Study disagreement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis ARNAUD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Caen University Hospital</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremlin-Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lille University Hospital</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyon Universty Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marseille University Hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Necher Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Curie Institute</name>
      <address>
        <city>Saint-Cloud</city>
        <zip>92000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Réunion University Hospital</name>
      <address>
        <city>Saint-Paul</city>
        <zip>97000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Institute</name>
      <address>
        <city>Villejuif</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 16, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Blastoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

